Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEn 1123

Next Previous
X
Search
Drug Profile

GEn 1123

Alternative Names: GEn-1123

Latest Information Update: 08 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Maryland, Baltimore
  • Developer GEn1E Lifesciences
  • Class Urologics
  • Mechanism of Action Immunomodulators; Mitogen-activated protein kinase 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Kidney disorders

Most Recent Events

  • 16 Jan 2024 Preclinical trials in Kidney disorders in USA (PO) prior to January 2024 (GEn1E Lifesciences pipeline, January 2024)
  • 17 Oct 2018 GEn1E Lifesciences enters into an exclusive option agreement with University of Maryland, Baltimore to license selective p38 MAP kinase inhibitors
  • 22 Jun 2017 University of Maryland, Baltimore has patent pending for 'Non-catalytic substrate-selective p38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity and methods of use thereof' in the World

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top